Ophiomics secured a Series A investment round to support commercial development and continued technical/clinical development of its flagship product HepatoPredict, and to further support the development of a portfolio of products focused on early cancer detection and cancer patient stratification for treatment selection.
Ophiomics completed a funding round fully covered by funds managed by Portuguese venture capital firm BlueCrow.
BlueCrow’s investment aims to develop the commercial aspects of HepatoPredict, bringing it to the global market, whilst still looking to enhance the product’s clinical validation and continued technical development. In addition, it aims to fund the development of a portfolio pf cancer-directed precision medicine solutions, in particular of a liquid biopsy test for early detection of liver cancer, among others.
Founded by José Leal and Joana Vaz, experts in Bioinformatics and Genomics, respectively, Ophiomics is a Biotechnology company specialized in precision medical solutions in oncology, specifically in-vitro diagnostic medical devices, integrating genomics, bioinformatics and artificial intelligence as pillars of their R&D.
For José Leal, “This investment will enable the commercial development of HepatoPredict for the global market, whilst allowing for the development of other innovative molecular tests that further contribute to reducing the scourge of early death from liver and other gastrointestinal tract cancers. “
Bernardo Empis Meira, Partner at BlueCrow, adds “we share the same goal of contributing to solutions that save lives and have a relevant impact on increasing societal quality of life. The Ophiomics team has done an extraordinary job in oncology research“.